









Markets
/
Stocks
/
nasdaq-indv
/

Indivior PLC

INDV

30.880USD

-0.460-1.47%

Close 11/10, 16:00（ET）Quotes delayed by 15 min

3.86BMarket Cap

33.57P/E TTM



Indivior PLC

30.880

-0.460-1.47%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Indivior PLC

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Indivior PLC's Score

Industry at a Glance

Industry Ranking

9 / 159

Overall Ranking

35 / 4611

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

36.714

Target Price

+17.15%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Indivior PLC Highlights

StrengthsRisks

Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 31.85% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 31.39, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 118.02M shares, increasing 2.08% quarter-over-quarter.

Held by Howard Marks

Star Investor Howard Marks holds 11.01M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-10

The company's current financial score is 8.86, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 314.00M, representing a year-over-year increase of 2.28%, while its net profit experienced a year-over-year increase of 950.00%.

Score

Industry at a Glance

Previous score

8.86

Change



Financials

7.32

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.39

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.59

Key Metrics

Free cash flow

No Data

Indivior PLC's Company Valuation

Currency: USD Updated: 2025-11-10

The company’s current valuation score is 6.87, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 31.39, which is 2528.16% below the recent high of 825.08 and 371.63% above the recent low of -85.28.

Score

Industry at a Glance

Previous score

6.87

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 9/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-10

The company’s current earnings forecast score is 8.57, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Indivior PLC is 36.00, with a high of 41.00 and a low of 28.00.

Score

Industry at a Glance

Previous score

8.57

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

36.714

Target Price

+17.15%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Indivior PLC

INDV

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-10

The company’s current price momentum score is 9.27, which is higher than the Pharmaceuticals industry's average of 7.09. Sideways: Currently, the stock price is trading between the resistance level at 34.31 and the support level at 25.56, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.36

Change

-0.09

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.975

Buy

RSI(14)

73.620

Buy

STOCH(KDJ)(9,3,3)

85.141

Neutral

ATR(14)

1.468

High Vlolatility

CCI(14)

61.471

Neutral

Williams %R

18.347

Overbought

TRIX(12,20)

1.200

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

31.628

Sell

MA10

29.799

Buy

MA20

27.268

Buy

MA50

25.120

Buy

MA100

21.949

Buy

MA200

16.353

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-10

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Oaktree Capital Management, L.P.

Star Investors

11.01M

Deerfield Management Company, L.P.

10.57M

Two Seas Capital LP

10.33M

-11.43%

Goldman Sachs International

8.97M

+9.24%

BlackRock Investment Management (UK) Ltd.

8.27M

+28135.71%

Madison Avenue Partners LP

7.92M

+1.67%

BlackRock Institutional Trust Company, N.A.

5.04M

+68055.48%

Rubric Capital Management LP

4.65M

-1.17%

Point72 Asset Management, L.P.

Star Investors

3.57M

+89.42%

The Vanguard Group, Inc.

Star Investors

5.63M

+22.15%

Risk Assessment

Currency: USD Updated: 2025-11-10

The company’s current risk assessment score is 6.76, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 1.10. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.